Cargando…

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response

BACKGROUND: Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen receptor-positive / HER2-negative breast cancer (ER+/HER2- BC) but monitoring of tumor response is challenging. The aim of the present study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boughdad, Sarah, Champion, Laurence, Becette, Veronique, Cherel, Pascal, Fourme, Emmanuelle, Lemonnier, Jerome, Lerebours, Florence, Alberini, Jean-Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986018/ https://www.ncbi.nlm.nih.gov/pubmed/31992361 http://dx.doi.org/10.1186/s40644-020-0287-4

Ejemplares similares

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
por: Saita, Chiaki, et al.
Publicado: (2016)

Morphologic predictors of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Zhang, Chongda, et al.
Publicado: (2017)

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer
por: Tury, Sandrine, et al.
Publicado: (2016)

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
por: Bonnefoi, Hervé, et al.
Publicado: (2019)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Dual time point [(18)F]FLT-PET for differentiating proliferating tissues vs non-proliferating tissues
por: Lovinfosse, Pierre, et al.
Publicado: (2019)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death
por: Le Scodan, Romuald, et al.
Publicado: (2011)

Influence of age on radiomic features in (18)F-FDG PET in normal breast tissue and in breast cancer tumors
por: Boughdad, Sarah, et al.
Publicado: (2018)

Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting—initial results
por: Moisander, Mikko, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and pathologic response: a retrospective cohort
por: de Andrade, Diocésio Alves Pinto, et al.
Publicado: (2013)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
por: Pennisi, Angela, et al.
Publicado: (2016)

Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer
por: Ren, Dong-Lin, et al.
Publicado: (2019)

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
por: Kunnuru, Supreeth Kumar Reddy, et al.
Publicado: (2020)

Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer
por: Wittmann, David, et al.
Publicado: (2020)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
por: Liebscher, Sean C., et al.
Publicado: (2023)

Endocrine Pathology of the Ovary
por: Ober, William B.
Publicado: (1958)

The Spectrum of Endocrine Pathology
por: Asa, Sylvia L., et al.
Publicado: (2023)

Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial
por: Reis, Joana, et al.
Publicado: (2021)

The Impact of Complex Rehabilitation Treatment on Sarcopenia—Pathology with an Endocrine Morphological Substrate and Musculoskeletal Implications
por: Stanciu, Liliana-Elena, et al.
Publicado: (2023)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
por: Zhang, Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ultgsa15mnn4nvqt8gqdpe8p0a